PHARMACOKINETIC AND PHARMACODYNAMIC STUDY OF SURICLONE IMIPRAMINE INTERACTION IN MAN

Suriclone is a novel cyclopyrrolone exhibiting anxiolytic activity. Tw elve healthy Causasian male volunteers participated in the study. A si ngle dose of suriclone 0.4 mg, imipramine 75 mg, suriclone 0.4 mg + im ipramine 75 mg, or placebo was given according to a 4 x 4 Latin-square design in order to assess the effect of drug association on pharmacok inetics and psychomotor performances. Visual analogue scale ratings, c ritical flicker frequency, choice visual reaction time, and Pauli, pic ture memory and Sternberg tests were performed before and 1.5, 6 and 9 h after drug administration. Suriclone, with the exception of the Pau li test, had no effect on psychomotor performances. The imipramine-sur iclone association appeared to disturb some performances (no statistic al significance), probably due to the effect of imipramine. Blood samp les were collected for determination of imipramine and suriclone plasm a levels respectively by high-performance liquid chromatography and ra dioimmunoassays. Suriclone AUC, C-max and T-max were not affected by i mipramine, and reciprocally.